Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.38 |
| ▸ | HTT | P42858 | 2/20 | 0.38 |
| ▸ | CA1 | P00915 | 4/20 | 0.36 |
| ▸ | CA2 | P00918 | 4/20 | 0.36 |
| ▸ | CA12 | O43570 | 3/20 | 0.36 |
| ▸ | CA9 | Q16790 | 3/20 | 0.36 |
| ▸ | F2 | P00734 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 3/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | MGLL | Q99685 | 2/20 | 0.35 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.35 |
| ▸ | PHGDH | O43175 | 1/20 | 0.35 |
| ▸ | ALDH2 | P05091 | 1/20 | 0.35 |
| ▸ | FBP1 | P09467 | 1/20 | 0.35 |
| ▸ | ALPG | P10696 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10177631 | 0.97 | — | — | |
| SCHEMBL6778480 | 0.97 | — | — | |
| SCHEMBL10143716 | 0.97 | — | — | |
| SCHEMBL10145581 | 0.78 | KMT2A (0.39) | KMT2AALDH1A1HTTCA1CA2 | |
| SCHEMBL12132349 | 0.78 | KMT2A (0.39) | KMT2AALDH1A1HTTCA1CA2 | |
| SCHEMBL8297623 | 0.74 | — | — | |
| SCHEMBL10143226 | 0.74 | — | — | |
| SCHEMBL19861950 | 0.74 | SMN1; SMN2 (0.50) | KMT2AALDH1A1HTTCA1CA2 | |
| SCHEMBL8285005 | 0.72 | — | — | |
| SCHEMBL21674243 | 0.72 | KMT2A (0.36) | KMT2AALDH1A1HTTCA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6759419-B2 | NOOTROPIC AGENTS; BRAIN DISORDERS; ALZHEIMER'S DISEASE | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2004-07-06 | — | — | US | disclosed |
| US-20030114491-A1 | Pyrrolidinone derivatives, their preparation and pharmaceutical composition comprising the same | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2003-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030114491-A1 | Pyrrolidinone derivatives, their preparation and pharmaceutical composition comprising the same | CHRM1, CHRNA5, CHRNA7 | KMT2A 1734/4885ALDH1A1 1474/4885HTT 2015/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.